Abstract Nuclear Warfare and nuclear leakage can result in a large number of patients with radiationinduced bone marrow damage. Based on the fact that hematopoietic stem cells and hematopoietic growth factors are characterized as a novel strategy for therapy, the aim of this study was to explore a safe and routine stem cell/cytokine therapeutic strategy. Allogeneic multiplacenta derived hematopoietic and mesenchymal stem cells/cytokines were intraperitoneally injected into a moderate dose of total body irradiation-induced mouse bone marrow damage model a single time. Then, the mouse posttransplantation survival time, peripheral blood hemoglobin count, bone marrow architecture, and donor cell engraftment were assessed. Each mouse that received placenta-derived stem cells exhibited positive donor hematopoietic and mesenchymal stem cell engraftment both in the bone marrow and peripheral blood after transplantation. The peripheral blood hemoglobin count and survival time were greater in the group with the combined treatment of multiplacenta-derived stem cells and cytokines, compared with model-only controls (both P \ 0.001). The blood smear mesenchymal/hematopoietic stem cell count was significantly higher in the combined treatment group than in the mice treated only with placenta-derived cells (28.08 ± 5.824 vs. 20.40 ± 5.989, P \ 0.001; 7.74 ± 2.153 vs. 4.23 ± 1.608, P \ 0.001, respectively). However, there was no marked change on the bone marrow pathology of any of the experimental mice after the transplantation. These results indicate that for radiation-induced bone marrow damage treatment,
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Introduction
Nuclear events, radiological terrorism, and radiation accidents result in a large number of patients with radiation-induced bone marrow damage Koenig et al. 2005; Pellmar and Rockwell 2005; Mettler and Voelz 2002) . It is a refractory disease that has a high fatality rate with pancytopenia. However, there is currently a lack of therapeutic agents that are safe, effective, and approved for patient care (Augustine et al. 2005; Coleman et al. 2003) . Hematopoietic stem cells and hematopoietic growth factors have been shown to be effective treatments for radiation-induced bone marrow damage Audet et al. 2002; Waselenko et al. 2004; Hirama et al. 2003; Vávrová et al. 2002) . However, problems of donor deficiency, high mortality for conditioning, and complications resulting from transplantation are still associated with these treatments (Hu et al. 2010) .
The microenvironment in bone marrow consists of stromal cells derived from mesenchymal stem cells (Hu et al. 2010) . Hematopoietic stem cells and bone marrow microenvironment damage are aggravated after radiation-induced injury (Greenberger et al. 1996) . Therefore, either the hematopoietic or the mesenchymal stem cells are indispensable for hematopoietic recovery. It has been reported that placental extracts have anti-oxidative and anti-inflammatory activities (Banerjee et al. 1992; Togashi et al. 2000; Sur et al. 2003; Park et al. 2010 ). In addition, immunological mechanisms may facilitate engraftment in donors receiving two unrelated umbilical cord blood units (David McKenna and Sheth 2011) . Using a mouse model, we have ascertained that intraperitoneal transplantation of multiplacenta-pooled cells can delay the development of aplastic anemia (Li et al. 2016) . Considering that the placenta contains abundant cytokines as well as hematopoietic and mesenchymal stem cells, it is plausible that treatment with multiplacenta-derived stem cells/cytokines can improve hematopoietic recovery.
The placenta is readily available, and placental cells injected intraperitoneally have a low toxicity over a wide dose range (Ghionzoli et al. 2010; Piscaglia et al. 2005 ). The present study was undertaken to examine the therapeutic effect and cellular mechanism of multiplacenta-derived stem cells/cytokines on mice with radiation-induced bone marrow damage mediated with a moderate dose of total body irradiation. This analysis was accomplished by observing the peripheral blood hemoglobin count, posttransplantation survival time, bone marrow architecture, and donor cell engraftment.
Materials and methods

Mice characteristics
Two-month-old inbred female H2d BALB/cBy recipient mice were purchased from Google Organisms. The donor C57BL/6J F1 mice (H2b) were provided by the Neuroscience Institute of Kunming Medical University (Kunming, Yunnan, China). All mice were maintained in the Specific Pathogen-Free Aanimal Facility of Kunming General Hospital of Chengdu Military Command. The animal studies were approved by the local institutional review board of Kunming General Hospital of Chengdu Military Command. 650 BALB/cBy mice were equally divided into the healthy normal control group (control group) and four experimental groups: the model only control, the multiplacenta-derived cell treatment group, the multiplacentaderived cytokine treatment group, and the group of combined treatment of multiplacenta-derived cells and cytokines, with a complete randomized design. Then, each group was equally divided into two subgroups (life-span and detection) at random. Each subgroup contained 65 mice. The posttransplantation survival time was only observed in mice in the lifespan subgroup while peripheral blood hemoglobin count, bone marrow architecture, and donor cell engraftment were detected in mice in the detection subgroup. These two groups were used to rule out that these detection methods had an influence on the assessment of posttransplantation survival time.
Induction of a radiation-induced bone marrow damage model
The BALB/cBy mice were irradiated on a rotating platform and received a sublethal dose of 4.5 Gy total body irradiation from a JL Shepherd Model 143 137 Cesium c-irradiator (JL Shepherd, Glendale, CA, USA) at a rate of 2.0 Gy/min. Then, the mice were ready for treatment with multiplacenta-derived cells/cytokines.
Preparation of multiplacental cells
Several placentas (containing the placenta, umbilical cord and umbilical cord blood) of donor C57BL/6J F1 mice with no green fluorescent protein expression were mixed together, ground, and filtered with Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12, Gibco BRL, Life Technologies, Grand Island, NY, USA) through a 200-eye cell sieve mesh to obtain the same mL of placenta-derived cell/cytokine suspension as the number of placenta. The suspension was centrifuged at 750 g for 5 min to separate it into placenta-derived cytokines supernatant and placenta-derived cells two parts. Thus, the cytokines suspension was ready for use. The mixed cells from the sieve mesh were cultured in DMEM/F-12 with adherent culture to sort the mesenchymal stem cells. The P2 generation of mesenchymal stem cells was identified and marked with Hoechst 33258 (Invitrogen, Eugene, OR, USA). Mouse multiplacentapooled hematopoietic stem cells (Lin -c-kit ? Sca1
? cells) were sorted from green fluorescent proteinexpressing transgenic inbred parturient C57BL/6J mice as reported previously (Li et al. 2016; Meng et al. 2003; Wang et al. 2006) . The stem cells were washed three times in DMEM/ F-12 and counted using a Vi-Cell counter (Coulter Cooperation, Fullerton, CA, USA) (Li et al. 2012) . Then, 1 9 10 4 mesenchymal stem cells were mixed with 1 9 10 4 green fluorescent hematopoietic stem cells in 1 mL of DMEM/F-12. The cells were ready for use in the multiplacenta-derived cell-only treatment group.
At last, 1 9 10 4 mesenchymal stem cells mixed with 1 9 10 4 hematopoietic stem cells in 1 mL of cytokines suspension were ready for use in the combined treatment group.
Multiplacenta-derived cell/cytokine treatment A total of 1 mL of 10 8 mixed stem cell suspension in DMEM/F-12 was intraperitoneally injected into BALB/cBy recipient mice of the multiplacentaderived cell treatment group at 1 9 10 8 cells per mouse a single time within a few hours after total body irradiation. The cytokines suspension in DMEM/F-12 was intraperitoneally injected into the model mice in the multiplacentas derived cytokine treatment group at 1 mL per mouse a single time. Then, 1 mL of 10 8 mixed cell in cytokine suspension was intraperitoneally injected into the mice of the combined treatment group as well as the above groups. The model-only control mice received the same volume of DMEM/F-12, while healthy normal controls did not receive any treatment.
Posttransplantation survival time, peripheral blood hemoglobin level, bone marrow histology, and donor cell engraftment detection After transplantation, the survival time of mice in lifespan subgroup were examined and compared to define the treatment effectiveness. The peripheral blood hemoglobin count was detected to propose the direct reason for longevity; bone marrow histology was observed to reveal stem cell regeneration and myeloid tissue restitution; and donor cell engraftment was detected in the blood smear and bone marrow smear before mouse death to trace the transplanted cells and assess cell survival and quantity. So, when mice started to die, mice in the detection subgroup were initially bled for peripheral blood donor cell engraftment detection and hemoglobin measurement. Then, the mice were sacrificed to collect the left and right femurs for marrow donor cell engraftment and architecture examination, respectively, as reported previously (Li et al. 2016) . The peripheral blood and the bone marrow were diluted with the same multiple DMEM/F-12 to detect the donor cells.
Statistical analysis
Means and standard deviation were used to describe the mouse characteristics. Group differences were analyzed by one-way analysis of variance. When only a single experimental group and the control group were compared, the variance was examined by the independent-samples t test. Differences were considered significant at P \ 0.05. All analyses were performed using SPSS 18.0 software.
Results
All animals in the detection subgroup were bled and sacrificed for analyses when some mice were dying at day 6 after transplantation.
Peripheral blood hemoglobin
Peripheral blood hemoglobin measurement was performed in a hematology analyzer. The hemoglobin count was as high as 1.3182 ± 0.02727 in the healthy normal controls, which was significantly higher than that in all the experimental groups (all P \ 0.001). Moreover, in all experimental groups, only the hemoglobin count of the combined treatment group was higher than that in the model-only control mice (0.1811 ± 0.02884 vs. 0.1332 ± 0.02784, P \ 0.001, Fig. 1 ).
Posttransplantation survival time
Mice in the life-span subgroup of the healthy normal control group all survived until 1 month after transplantation. However, 100 % mortality was induced with radiation-induced bone marrow damage (lifespan subgrous of the other groups) within 19 days. Thus, the posttransplantation survival times of mice in the life-span subgroups were compared at 1 month after treatment. The survival time in the healthy normal control group (30.000 ± 0.000 days) was significantly higher (all P \ 0.001) than those of all experimental groups. Among all experimental groups, only the survival time of the combined treatment group (13.120 ± 2.065 days) was longer (P \ 0.001) than that of the model-only control mice (9.830 ± 1.808 days, Fig. 2 ).
Bone marrow architecture
Bone marrow histology was observed in both the healthy normal and experimental groups.
Hematoxylin and eosin staining of the bone marrow showed myeloid tissue edema and bone marrow depression in all experimental mice, compared with the healthy normal controls that showed a dense cell distribution in normal conditions (Fig. 3) . Fig. 1 Mouse peripheral blood hemoglobin count at day 6 after treatment. The hemoglobin count in the healthy normal control group was significantly higher than that of all other groups. In addition, the hemoglobin count of the combined treatment group was higher than that of the model-only control mice. HGB hemoglobin (n = 65). *P \ 0.001 vs. Healthy normal control,
• P \ 0.001 vs. Model-only control 
Identification of donor cells
Fifty smear images were obtained for each group of mice, and placenta-derived fluorescent cells were observed. Every mouse that received 10 8 placentaderived cells exhibited positive donor cells of hematopoietic and mesenchymal stem cell engraftment in both the bone marrow and peripheral blood at 6 days after transplantation, while the other groups of mice did not show any positive cells (data not shown). There were plenty of blue donor mesenchymal and green hematopoietic stem cells on the blood smears of the group treated only with placenta-derived cells as well as the combined treatment group. The blood smear mesenchymal/hematopoietic stem cell count was significantly higher in the combined treatment group than in the mice only treated with placentaderived cells (28.08 ± 5.824 vs. 20.40 ± 5.989, P \ 0.001; 7.74 ± 2.153 vs. 4.23 ± 1.608, P \ 0.001, respectively). However, there were a few mesenchymal and hematopoietic stem cells in the bone marrow smears of both groups. There were no significant differences in the hematopoietic or mesenchymal stem cell counts in the bone marrow smears between the two groups (Fig. 4) .
Discussion
In the present study, the mice of each group were divided into life-span and detection subgroups. The survival time of the healthy normal control group was longer than that in the life-span subgroups of the other groups, so the survival time of mice was compared at the time point of 1 month after transplantation when all mice in the lifespan subgroup of the healthy normal control group had still survived. This time point avoided the unnecessary death of mice for the study.
Total body irradiation can cause long-term bone marrow suppression by inducing chronic oxidative stress and senescence in hematopoietic stem cells (Shao et al. 2014) . In the present study, the peripheral blood hemoglobin count, posttransplantation survival time, and bone marrow architecture were compared between the model-only control group and the healthy normal control group. All differences were significant. The data revealed that intentional exposure to a moderate dose of total body irradiation successfully induced bone marrow damage.
The current study evaluated the therapeutic effect and cellular mechanism of placenta-derived stem cells/cytokines on radiation-induced bone marrow damage. The peripheral blood hemoglobin count, posttransplantation survival time, and bone marrow architecture data showed that neither the multiplacenta-derived stem cells nor cytokines alone can delay disease development. Only intraperitoneal co-injection of multiplacenta-derived stem cells and cytokines can increase the life span of aplastic anemia model mice, and transplants are capable of delaying but not abrogating its development.
We administrated the stem cells only a single time in order to avoid an immunological response induced by repeated administration (Farese et al. 1996; Hérodin et al. 2003) . The cytokines in the recipient mice after irradiation are comparatively scarce because cell factor receptors are damaged and the tolerance of cytokine receptors is high (Quelle et al. 1998; MacVittie 1997) . Thus, we transplanted the stem cells combined with placentapooled cytokines. Placenta-derived mesenchymal and hematopoietic stem cells as well as cytokines are homologous (Kadekar et al. 2015) , and the cytokines combined with DMEM/F-12 can maintain the survival of the mesenchymal and hematopoietic stem cells.
Mesenchymal stem cells are strongly sticky and can adhere to the peritoneum, which can support and carry it into the blood circulation (Blazar et al. 1995) . The level of hepatocyte growth factor expression has been shown to be much higher in placenta-derived mesenchymal stem cells, compared to adult mesenchymal stem cells (Zhu et al. 2014) . Mesenchymal stem cells can produce a large number of interleukin (IL)-6, IL-7, IL-11, stromal cell-derived factor, leukemia inhibitor factor, stem cell factor, and Flt3 ligand, which are several essential hematopoietic growth factors (Grebnev et al. 2015; Chaudhary et al. 1992; Tolar et al. 2010; Zhang et al. 2011; Dazzi et al. 2006; Yañez et al. 2006; Sorrentino et al. 2008 ). IL-6 can activate the immune and hematopoietic systems (Lazzari et al. 2001) . IL-11 can enhance the proliferation of all blood cell lineages (Van derMeeren et al. 2002) . Stromal cell-derived factor induces transendothelial migration of hematopoietic stem cells to the bone marrow. All these are important factors in hematopoietic stem cell growth and multiplication (Majumdar et al. 1998 ). Moreover, IL-7, IL-11, stem cell factor, and Flt-3L have radioprotective effects (Yañez et al. 2006) , and e Bone marrow smear of mice treated with placenta-derived cells. f Bone marrow smear of mice treated with the combined treatment. The blood smear mesenchymal/hematopoietic stem cells count was significantly higher in the combined treatment group, compared to the group treated only with placenta-derived cells (both P \ 0.001, n = 65). However, there were no significant differences in the hematopoietic or mesenchymal stem cell counts in the bone marrow smears between the two groups Cytotechnology (2016 Cytotechnology ( ) 68:2677 Cytotechnology ( -2686 Cytotechnology ( 2683 mesenchymal stem cells can protect hematopoietic cells from apoptosis and enhance the cell-cycle transition after irradiation (Hu et al. 2010; Noll et al. 2002; McNiece et al. 2004) . Therefore, mesenchymal stem cells can promote the survival and engraftment of hematopoietic stem cells. The placenta contains a higher proportion of more primitive hematopoietic cells than the bone marrow (Smogorzewska et al. 1997) . Placenta-derived hematopoietic stem cells have a greater proliferative response to cytokines than the corresponding cells in the bone marrow or peripheral blood (Smogorzewska et al. 1997; Zhou et al. 2001 ). On CD34 ? placenta-pooled hematopoietic stem cells, there is a higher expression of adhesion molecules than in the same cells of the bone marrow or peripheral blood. All these may contribute to the engraftment of hematopoietic stem cells in the bone marrow..
The donor cell engraftment data show that the number of donor hematopoietic and mesenchymal stem cells in the combined treatment group was significantly higher than in the mice only treated with placenta-derived cells. In addition, the number of stem cells on the blood smear far exceeded that in the bone marrow smear, and the peripheral blood mesenchymal stem cell count in the blood smear was much higher than that of the hematopoietic stem cells. These findings suggest that cytokines boost the survival of mesenchymal stem cells and engraft then into the host body through the blood circulation (Li et al. 2016) . Mesenchymal stem cells can promote the survival and engraftment of the hematopoietic stem cells in the peripheral blood. So, the hematopoietic stem cells improve the peripheral blood hemoglobin count and thus prolong the posttransplantation survival time.
The bone marrow pathology data demonstrated that the radiation damage is too serious for a few donor hematopoietic and mesenchymal stem cells to restore the bone marrow architecture. The mice died before the hematopoietic stem cells could act on the bone marrow. Taken together, the transplants cannot abrogate the development of bone marrow injury.
Conclusion
The results from this study demonstrate that the intraperitoneal transplantation of multiplacentaderived mesenchymal and hematopoietic stem cells and cytokines can increase the life span of radiationinduced bone marrow damage model mice and delay but not abrogate disease progression. Intraperitoneally transplanted stem cells can survive and engraft into the host body through the blood circulation. Improvement of peripheral blood hemoglobin levels, but not the bone marrow architecture response, probably explains the increase in the posttransplantation survival time observed in this study. Therefore, the intraperitoneal injection of a large dose of multiplacenta-derived stem cells and cytokines at a single time may be a putative therapeutic strategy for the recovery of radiationinduced bone marrow damage.
